Lantern Pharma (LTRN) Total Current Liabilities (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Total Current Liabilities came in at $3.8 million in Q1 2026, down 11.88% YoY from $4.3 million in Q1 2025, and down 16.09% on a QoQ basis from $4.5 million in Q4 2025.
Lantern Pharma (LTRN) Total Current Liabilities (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Total Current Liabilities data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Total Current Liabilities fell 11.88% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 11.88% YoY) and the FY2025 annual result came in at $4.5 million, up 3.93% from the prior year.
- Total Current Liabilities declined to $3.8 million in Q1 2026, from $4.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $5.3 million in Q2 2022 to a low of $2.3 million in Q3 2023.
- A 5-year average of $3.7 million and a median of $3.8 million in 2026 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 362.56% — and 2023, when it plunged 43.14%.
- Tracing LTRN's Total Current Liabilities over 5 years: stood at $2.8 million in 2022, then decreased by 4.29% to $2.7 million in 2023, then soared by 61.72% to $4.3 million in 2024, then rose by 3.93% to $4.5 million in 2025, then retreated by 16.09% to $3.8 million in 2026.
- The last three Total Current Liabilities figures came in at $3.8 million (Q1 2026), $4.5 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 4.29 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 3.02 Mn |
| Mar 31, 2023 | 2.79 Mn |
| Dec 31, 2022 | 2.80 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 5.30 Mn |
| Mar 31, 2022 | 3.07 Mn |
| Dec 31, 2021 | 2.33 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 2.69 Mn |